

**CARDIO
RUN
2023**



**15^{ème} CONGRÈS
DE PATHOLOGIE
CARDIO-VASCULAIRE**





ANGOR MICRO-CIRCULATOIRE : diagnostic et prise en charge

**Dr Léo CUENIN
Saint-Laurent-du-Var**


ARBRE CORONAIRE



Pries et al. 2015 Eur Heart J 36(45): 3134-3146





ISCHEMIE MYOCARDIQUE





Syndrome coronaire stable

Syndrome coronaire instable




ISCHEMIE MYOCARDIQUE

Mechanisms of myocardial ischaemia



CENTRAL ILLUSTRATION: INOCA in the ISCHEMIA Study



Reynolds HR, et al. J Am Coll Cardiol Img. 2023;16(1):63-74.







FIGURE 4 Coexistence of Coronary Functional Abnormalities

Overall n = 187



CENTRAL ILLUSTRATION Vasospastic Angina and High Index of Microcirculatory Resistance: Prognostic Impact of Coexistence



PRONOSTIC

**Randomized
151 Patients**




**Angina & No
Obstructive CAD**

Intervention
Invasive Coronary
Function Guided
Care (n=75)




Control
Angiography guided
Care (n=76)

Linked Diagnosis:
Microvascular angina
Vasospastic angina
Non-cardiac



Therapy:
Stratify Antianginals
Non-pharmacological

Main Results:




**Sustained Benefits:
Improved Angina and
Quality of Life**

CAS CLINIQUE: Patient 47 ans


- HTA, dyslipidémie, tabac sevré
- **SCA ST- 2020** : 1 stent IVA moyenne → **Thrombose de stent à 1 mois** → stent FE 40% sur séquelle antérieure
- ttt : ASPIRINE, ATORVASTATINE, COSIMPREL
- **Angor d'effort et de repos** depuis 2 mois





CORONAROGRAPHIE





CONSENSUS : DIAGNOSTIC



CONSENSUS : EVALUATION NON INVASIVE



CONSENSUS : EVALUATION INVASIVE



RECHERCHE DE SPASME




EVALUATION HEMODYNAMIQUE



Guide FFR IVA distale

En direct

ANGIOPLASTIE IVA




REEVALUATION DE LA MICROCIRCULATION



CONCLUSION CAS CLINIQUE

Mechanisms of myocardial ischaemia



CONSENSUS : TRAITEMENT

Management of INOCA

1. Lifestyle factors



Nutrition



Exercise



Weight management



Smoking cessation



Coping with stress

2. Risk factor management



Hypertension



Dyslipidaemia



Diabetes mellitus

3. Antianginal medication



Microvascular angina


Consider statins and ACEI/ARB



Vasospastic angina

1. ~~Betablocker~~
2. Calcium channel blocker
3. Nicorandil
4. Ranolazine
5. Ivabradine
6. Trimetazidine

1. Calcium channel blocker
2. Long-acting nitrate
3. Nicorandil



7. Place du sinus reducer ?

TAKE HOME MESSAGE / INOCA

